Sala de prensa


Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

DURHAM, NC – June 16, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…

Read More

Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro

Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model DURHAM, NC – May 25, 2021 – Bioventus Inc. (Nasdaq:…

Read More

Bioventus Senior Management to Present at Upcoming Investor Conferences

DURHAM, NC – May 17, 2021 – Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for…

Read More

Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance

DURHAM, NC – May 12, 2021 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today…

Read More

Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System

Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution VALENCIA, CA – April 27, 2021 – Bioventus Inc. (Nasdaq: BVS)…

Read More

Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

DURHAM, NC - April 12, 2021 - Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…

Read More

Bioventus Acquires Bioness, Inc.

DURHAM, NC – March 30, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has…

Read More

Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance

DURHAM, NC – March 25, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…

Read More

Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS(TM) (PTP-001) for the Treatment of Knee OA

DURHAM, NC – March 11, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported…

Read More

Larry Chen Joins Bioventus as Managing Director, China and Asia Pacific

DURHAM, NC – March 4, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has…

Read More

Buscar noticias


Consultas de prensa


Thomas Hill
Director de Comunicaciones Corporativas
919.474.6715
[email protected]

Descargar biblioteca


Logotipos corporativos y de marca
Descargar ahora

Imágenes de productos
Descargar ahora